EP3934675A2 — Zilucoplan as deep tissue penetrating c5 inhibitor
Assigned to UCB Inc · Expires 2022-01-12 · 4y expired
What this patent protects
The present disclosure provides compounds, compositions, and methods for modulating complement activity. Included are C5 inhibitor compounds and related methods of use in treating complement-related indications.
USPTO Abstract
The present disclosure provides compounds, compositions, and methods for modulating complement activity. Included are C5 inhibitor compounds and related methods of use in treating complement-related indications.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.